SMALL CELL LUNG CANCER (SCLC)

This study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3, found in small cell lung cancer and similar tumors. About 138 adults with advanced cancer that has not responded to standard treatments will receive the drug to check safety, …

This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can keep extensive-stage small cell lung cancer from growing. About 35 adults who have already received initial chemotherapy and immunotherapy will re…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-spreading cancer. About 550 people who haven't had prior treatment for this stage will join. The goal is to see if the new combo works bett…

This early study tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has come back or not responded to standard treatments. The therapy uses specially engineered immune cells (CAR-T cells) to target a protein called DLL3 on…

This study tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest and most effective dose. About 150 participants will take th…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. About 65 adults who had their lung cancer completely removed will receive this combination. The goal is to see if it …

This early-phase study tests a new drug called 177Lu-RAD204, which is a radioactive antibody that seeks out and attaches to a protein (PD-L1) on cancer cells. The goal is to see if it is safe and tolerable for people with advanced solid tumors like lung, breast, or skin cancer th…

This early-stage study tests an experimental drug called mevrometostat in adults with advanced prostate cancer, small cell lung cancer, or follicular lymphoma that has stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug c…

This study tests a new medicine (PF-08634404) given with chemotherapy, then alone, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer. About 40 participants who have not yet been treated for T-SCLC will receive the drugs through IV infusions…

This early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple markers on small cell lung cancer cells. The goal is to see if these cells are safe and can shrink tumors in adults whose cancer has returned or not responded to standard …

This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in real-world settings. Researchers will track side effects and survival times in 500 patients. The goal is to see if this treatment helps control the diseas…

This early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…

This study tests a new drug called JAB-2485 in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. The trial is in early …

This study tests whether adding an experimental drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combi…

This study tests a new drug, peluntamig, in people with advanced neuroendocrine cancers (like small cell lung cancer) that have a specific marker called DLL3. The trial has two parts: first finding the safest dose, then testing it alone or with chemotherapy. About 203 participant…

This study tests a new radioactive probe called PFD3 that targets a protein (DLL3) found on small cell lung cancer cells. Using PET/CT scans, doctors hope to see tumors more clearly and assess the cancer's spread. About 30 adults with confirmed small cell lung cancer will receive…

This study is watching how lung cancer patients do when they get a drug called Tislelizumab in regular doctor visits, not in a strict research setting. About 240 people in Germany and Austria will take part. The goal is to see how long they live, how well the treatment works, and…